Celltrion Healthcare (Formerly Known As Celltrion)

1000 Marina Boulevard
Suite 200
Brisbane
California
94005
United States

Website: http://www.celltrionhealthcare.com/

About Celltrion Healthcare (Formerly Known As Celltrion)

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Jung Jini
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW CELLTRION:
Tweets by Celltrion

78 articles with Celltrion Healthcare (Formerly Known As Celltrion)

Celltrion, Inc.: No Difference In Efficacy Or Immunogenicity Following Switch To Remsima®? (Infliximab) From Originator

10/28/2015
Celltrion, Inc. Launches World’s First Biosimilar Monoclonal Antibody Remsima In 12 New European Markets

2/25/2015
Celltrion Healthcare: Data Show The World’s First European Medicines Agency-Approved Biosimilar Monoclonal Antibody Remsima Could Reduce Cost Of Treating Crohn’s Disease By Up To €336 Million Over Five Years

2/20/2015
Celltrion, Inc.: Experts Share Their “Real World” Experience Of Treating People With Inflammatory Bowel Disease (IBD) With Biosimilar Anti-Tnfa Monoclonal Antibody (Mab)

10/22/2014
Celltrion, Inc. Files For Approval Of Remicade Biosimilar In US

8/13/2014
South Korea's Celltrion, Inc. In Talks For Stake Sale

1/2/2014
Celltrion, Inc. Tumbles on Reports of Probe Into Share Trades

9/16/2013
AstraZeneca PLC Eyes Biosimilars, No Comment on Celltrion, Inc.

8/1/2013
Celltrion, Inc. Drops Late-Stage Trial of Roche Rituxan Drug Copy

4/19/2013
Celltrion, Inc.: Successful Development of Broad Spectrum Human Monoclonal Antibodies Against Major Influenza Viruses (H1N1 and H5N1)

3/9/2010
Hospira, Inc. (JOBS) in Deal with Celltrion, Inc. on Biogenerics

10/9/2009
Hospira, Inc., Celltrion, Inc. Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs

10/8/2009
Celltrion, Inc. and CSL Limited Announce Collaboration to Develop and Manufacture Monoclonal Antibody

1/10/2008
FDA Approves Celltrion, Inc. to Manufacture ORENCIA(R) (abatacept)

12/18/2007
VaxGen, Inc. Raises $51.3 Million Through Sale Of Interest In Celltrion, Inc.

1/3/2007
A&G Pharmaceutical, Inc. And Celltrion, Inc. Announce Bioprocess Development & Manufacturing Agreement For A&G Anti-GP88 Cancer Therapeutic Antibody - Deal Worth Up To $8.4 Million

6/7/2006
VaxGen, Inc. Advances Toward Filing Its Financial Statements As Celltrion, Inc. Completes Preparation Of U.S. GAAP Financial Statements

1/25/2006
Aphton Corporation Announces Closing of Commercialization and Manufacturing Agreements for IGN311 With Celltrion, Inc.

11/17/2005

First
Previous
1
2
3
4
Last